Platinum Compound-Related Ototoxicity in Children:... : Journal of Pediatric Hematology/Oncology (original) (raw)
Original Article
Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss
Bertolini, Patrizia MD; Lassalle, Mathilde MSc; Mercier, Guilaine MD; Raquin, Marie Anne MD; Izzi, Giancarlo MD; Corradini, Nadege MD; Hartmann, Olivier MD
From *Pediatric Hematology/Oncology, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy; †Biostatistics and Epidemiology Service, Institut Gustave-Roussy, Villejuif, France; ‡Groupe Recherche Audiologie Medicale, Paris, France; and §Department of Pediatrics, Institut Gustave-Roussy, Villejuif, France.
Received for publication December 20, 2003;
accepted July 26, 2004.
Reprints: Dr. Patrizia Bertolini, Department of Pediatrics, Onco-Hematology, Azienda Ospedaliera di Parma, Via Gramsci 14, 43100 Parma, Italy (e-mail: [email protected]).
Abstract
Objectives:
The purpose of this study was to evaluate the severity of hearing loss after cisplatin and/or carboplatin treatment in young children and to analyze its evolution and its relation to different therapy schedules.
Methods:
One hundred twenty patients treated in the Pediatrics Department at the Institut Gustave-Roussy from 1987 to 1997 for neuroblastoma, osteosarcoma, hepatoblastoma, or germ cell tumors were analyzed. Median age at diagnosis was 2.6 (range 0–17) years. Median follow-up was 7 (1–13) years. Chemotherapy regimens contained cisplatin and/or carboplatin. Three patients also received high-dose carboplatin. Cisplatin was administered at a dose of 200 mg/m2/course in 72% of cases. The median cumulative dose was 400 mg/m2 for cisplatin and 1,600 mg/m2 for carboplatin. Hearing loss of grade 2 or above, according to Brock’s grading scale, was revealed with pure tone audiometry and behavioral techniques.
Results:
Carboplatin alone was not ototoxic. Deterioration of hearing of grade 2 or above was observed in 37% of patients treated with cisplatin and 43% of patients treated with cisplatin plus carboplatin (P = NS). Fifteen percent of patients experienced grade 3 or 4 ototoxicity. Ototoxicity was most often observed after a total cisplatin dose of at least 400 mg/m2. No improvement was observed with time; on the contrary, worsening or progression of hearing loss at lower frequencies was detected during follow-up. Only 5% of audiograms showed toxicity of at least grade 2 before the end of therapy; in contrast, this level was observed in 11% of early post-therapy evaluations and in 44% after more than 2 years of follow-up.
Conclusions:
Children treated with cisplatin at cumulative doses approaching 400 mg/m2 require long-term surveillance to avoid overlooking hearing deficits. Carboplatin, at a standard dose, does not appear to be a significant risk factor for ototoxicity even in patients who have already been treated with cisplatin.
Copyright © 2004 Wolters Kluwer Health, Inc. All rights reserved.